Tariffs and the MedTech Industry: Disruption, Realignment, and Strategic Consequences
To view our article as originally published in the March 2026 issue of Medical Product Outsourcing Magazine website, click here.
MedWorld Advisors hosted a panel last month at MD&M West about the ways in which tariffs are shaping organic and inorganic trends in global medtech markets. The key takeaway from that discussion was that supply chain strategies matter more than ever.
Even with built-in exemptions, the period of medical devices benefiting from minimal tariffs—thereby allowing manufacturers to optimize costs through globally distributed production—is in jeopardy due to current geopolitical economic dynamics. The industry, which had grown dependent upon global outsourcing (think China) since the late 1990s and early 2000s, has had to weather the turbulent tariff climate of late. Medtech companies face the possibility of steep import duties on critical components alongside heightened geopolitical uncertainty and retaliatory trade actions. It seems almost every day is bringing new dynamics that must be managed. C-suites are being forced to include tariff dynamics into their short-term and long-term strategies, and seek answers about the potential the strategic consequences.
When President Trump began his second term in 2025, the United States began to implement broad and aggressive tariff measures. With some exceptions, these measures affected medical devices and components from nearly all major trading partners across most all geographies. Currently, a universal 10% baseline tariff (with some nations facing even steeper increases) is being applied to most imported devices and components regardless of country of origin. Since the industry previously had a low and sometimes zero import duty, these new tariffs mark a significant shift.
Clearly, tariff rates are not all created equal. In China, levies can be as high as 54% for sourced devices and components. European Union imports, which previously were near duty free, now face a 20% tariff rate. And while goods compliant with the United States-Mexico-Canada Agreement (USMCA) remain duty free, noncompliant imports face 25% charges.
These changes, of course, didn’t occur in isolation. Enhanced trade volatility, retaliatory measures (notably, the EU’s reintroduction of retaliatory tariffs on certain U.S. medical-use products), and shifting geopolitical alliances have resulted in disrupted supply chains that depend heavily on cross-border manufacturing.
Naturally, there has been a ripple effect on global supply chains. Few industries are as globally interconnected as medtech, and that means these tariffs disputes are acutely felt by some industry players. Many medical devices require components and materials sourced from multiple continents, including specialty plastics, metals, electronics, and subassemblies. The new tariff regime introduces friction and cost increases at every stage of this chain, turning previously streamlined processes into the possibility of being risk-filled bottlenecks.
Reports show that 50% to 80% of components used in U.S-made devices are imported, meaning that even domestic production is now vulnerable to tariff-driven cost inflation. Raw materials are subject to increasing duties. Steel, aluminum, polymers, and electronic components—which are critical in everything from orthopedic implants to imaging equipment—are affected by these increases. In some cases, the industry is experiencing “tariff stacking,” where finished devices incur multiple layers of fees tied to each imported subcomponent.
Supply Chain Strategy Chatter
Besides M&A, the “talk” of the MD&M show floor was supply chain strategy amid the need for global footprints to meet regional (EU, North America, Asia) customer demands. Companies that once leaned heavily on China for low-cost components are re-evaluating this dependency. Many are moving toward a regional manufacturing model, producing goods within or near end markets to avoid cross-border tariff penalties. This shift, which accelerated after COVID-19 supply chain disruptions and is now amplified by the tariff climate, reflects a broader strategy by C-suites of decentralization and risk mitigation. Manufacturing “in the region for the region” is more important now than ever before.
Under tariff pressure, companies are forced to reconsider their innovation, product development, and M&A strategies for cost-effective organic and inorganic growth.
The dynamics of these tariff pressures are reshaping medtech, especially in the three aforementioned areas (innovation, product development, and M&A). As tariffs increase production costs in some supply chains and introduce new layers of potential uncertainty, companies are adapting in ways that highlight how impactful trade policy can be regarding the strategic direction of aligning medtech supply chains.
Some medtech companies are accelerating their digital transformation efforts (i.e., product lifecycle systems) to maintain agility and reduce compliance burdens tied to sourcing changes. Others are scaling back or postponing nonessential innovation initiatives. Companies with stronger margin profiles or highly differentiated products are better able to absorb cost increases, allowing them to continue funding innovation without significantly altering strategy. For many midsized or emerging companies, tariff-driven cost inflation creates financial pressures that can impact the ability to remain competitive, limit R&D execution ability, and reduce flexibility in exploring new clinical markets.
As such, these innovation constraints caused by tariffs are directly influencing the M&A landscape. Tariffs have heightened the strategic value of acquisitions that offer cost stability, supply chain resilience, or geographic diversification. For example, companies with U.S.-based manufacturing capacity or tariff-exempt production lines have become attractive targets for buyers seeking to strengthen domestic or USMCA-compliant supply chains. Firms are increasingly prioritizing vertical integration—acquiring suppliers of critical components, with the goal of reducing exposure to sudden tariff changes and secure control over manufacturing inputs. At the same time, global players exposed to foreign retaliatory measures, such as the EU’s reinstated tariffs on certain U.S.-manufactured medical-use goods, are rethinking their geographic footprint and exploring acquisitions that could bypass future tariff uncertainties. We are seeing first-hand examples of these M&A activities play-out in our practice.
Tariff pressures are also creating openings for opportunistic acquisitions. Smaller firms struggling with margin compression may become distressed targets, allowing larger companies to purchase them at more favorable valuations. In some cases, M&A is being used to protect or even accelerate innovation. By acquiring firms with insulated or domestic supply chains, medtech companies can maintain uninterrupted development pipelines and mitigate tariff-driven uncertainty. On the other hand, companies based in regions facing steep U.S. import duties—European device manufacturers encountering 20% tariffs for example—are exploring U.S. acquisitions to localize production and remain competitive in the vital U.S. market.
In summary, supply chain strategies matter, especially in an industry like medtech, which is under constant transformation. The current tariff environment has created a new normal for the sector, and this new normal is defined by rising costs, the need supply chain rebalancing, and strategic reinvention. Companies are responding by reshoring production, diversifying supplier networks, and using M&A to bolster resilience.
While tariffs present undeniable challenges, they also push the industry forward. Modernization, more robust regional manufacturing, and smarter long-term strategic planning are among the benefits. Utlimately, medtech has repeatedly shown its resiliency and ability to adapt. As geopolitical uncertainties persist, medical device firms that adapt with agility and foresight will be best positioned to thrive in the United States and abroad.
MORE FROM THESE AUTHORS: What 2026 Will Demand from Medtech Leadership in M&A
Florence Joffroy-Black, CM&AA, and Dave Sheppard, CM&AA, are managing partners, and Estelle Black is business operations director at MedWorld Advisors, a global M&A advisory firm serving the medical technology and life-science industries. Florence can be reached at florencejblack@medworldadvisors.com. Dave can be reached at davesheppard@medworldadvisors.com.
